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Abstract
Diffuse intrinsic pontine glioma (DIPG) is a leading cause of brain cancer-related death 
in children. These aggressive high-grade gliomas cannot be effectively treated and are 
associated with dismal prognosis. Whilst radiation therapy (RT) prolongs survival, it is 
a palliative therapy, as half of children with DIPG die within 1 year of diagnosis and 
almost all are dead by 2 years. These statistics have not changed for decades, despite a 
multitude of clinical trials. No chemotherapeutic regimen has been shown to improve 
survival, emphasizing the need to find novel and effective treatments. One of the princi-
pal reasons for this poor outcome was our limited knowledge of the biology of DIPG’s. 
Due to their location in brainstem, surgical resection is not feasible and up until recently, 
even performing a limited biopsy was considered too dangerous. In the last decade, 
DIPG tumor tissue has become available through autopsies and biopsies. This combined 
with the genome revolution has resulted in a transformation in our understanding of 
the underlying biology of this disease. Moreover, viable DIPG cells can now be grown 
in the laboratory which have allowed development of in-vitro (neurospheres) and in-vivo 
models (allograft and xenograft). This chapter summarizes recent advances in DIPG and 
potential novel therapies.
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1. Introduction
Diffuse intrinsic pontine glioma (DIPG) is a high-grade glioma originating in the pons and 
occurs predominantly in children. It is one of the most dreaded pediatric cancers as they are 
essentially incurable. At the same time, it has become one of the most intense areas of research 
in the past few years. Due to the lack of tumor samples, there was limited information avail-
able about the genetic and molecular abnormalities in DIPG. These tumors were considered 
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to mimic other pediatric and adult high-grade gliomas and therapies were based on these 
inaccurate assumptions. Radiation therapy (RT) is the only treatment modality available, that 
has been demonstrated to prolong survival and improve quality of life (ref) but is not cura-
tive. Almost all children die with a median survival of 1 year. Indeed, 50% of children with 
DIPG die within 1 year of diagnosis and almost all are dead by 2 years (ref). Despite a myriad 
of clinical trials, no effective treatment has been identified so far. But recently, there has been 
an exponential increase in the pre-clinical research involving DIPG and many, previously 
unknown, abnormalities contributing to DIPG pathogenesis have been identified. These may 
provide treatable targets and help improve the outcome of patients with DIPG.
2. Epidemiology
Tumors of the central nervous system (CNS) constitute the largest group of solid tumors and 
the second most common pediatric cancer [1, 2]. Around 20% of CNS tumors are brainstem 
gliomas [3] of which 80% arise within the pons as DIPG [4] with approximately 200–300 
children in the United States [5] being diagnosed each year. Survival rates for children with 
cancer have improved dramatically since the 1960s; from an estimated 5-year survival of 
28% to approximately 80–85% at present [6]. The outcome for patients diagnosed with brain 
tumors has also improved with more than 70% expected to survive at least 5 years from the 
diagnosis [7]. Pediatric CNS tumors are a very heterogeneous group of diseases with over 100 
distinct histological types and survival differs markedly amongst the different histological 
types. Unlike other childhood cancers, survival for DIPG has not changed [5]. The median 
survival for children with DIPG is less than 1 year from the diagnosis [8] with more than 90% 
dying within 2 years of diagnosis [4, 9]. Although DIPG constitute only 10–15% of all pediatric 
brain tumors, they are the leading cause of death in this group [10]. More than three decades 
of research and different treatment modalities have not yielded any survival improvement.
3. Clinical features
The symptoms and signs of patients with DIPG occur secondary to the involvement of dif-
ferent parts of the brainstem, which include the midbrain, pons and medulla. The brainstem 
serves as a conduit through which axonal tracts pass to the spinal cord, cerebrum or exit as 
cranial nerves. Due to the diffuse nature of DIPG, the tumor infiltrates the white matter affect-
ing the adjacent cranial nerves and white matter tracts [11]. As the pons contains important 
nuclei critical for life-sustaining function, any damage caused by the tumor or its treatment 
has devastating effects. DIPG predominantly occurs in in the middle childhood. Median 
age at diagnosis is 6–7 years, with males and females affected equally [11–13]. Interestingly, 
adults with DIPG tend to have a longer survival which may indicate a less aggressive and 
biologically different tumor from that in children [14]. Typically, the presentation is with 
neurological symptoms of less than 3 months duration [15] with the “classic” triad of cranial 
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nerve deficits (diplopia and facial asymmetry), long tract signs (hyperreflexia, clonus, upward 
Babinski, increased tone and decreased strength) and cerebellar signs (ataxia, dysmetria and 
dysarthria), which is seen in about 50% patients [16, 17]. In most cases, abducens nerve palsy 
is the earliest sign and is a sensitive predictor for DIPG [17]. Obstructive hydrocephalus with 
signs of raised intracranial pressure are seen in <10% of patients [18]. Other symptoms for 
example behavioral changes, night terrors, and school difficulties may also occur.
4. Imaging characteristics
4.1. Magnetic resonance imaging (MRI)
DIPG is diagnosed clinically on the basis of history, clinical signs and MRI findings [18]. The 
classic MRI appearance is of an expansile lesion centred in the pons that frequently extends 
laterally into the cerebellar peduncles and hemispheres and often extends vertically into the 
midbrain and medulla (Figure 1A). It is poorly marginated, occupying more than 50% of the 
axial diameter of the pons [11]. Necrosis can be seen but cysts are rare [14]. The tumors are 
hypointense with indistinct margins on T1-weighted images (Figure 1B) and hyperintense 
on T2-weighted/fluid-attenuated inversion recovery (FLAIR) images (Figure 1C and D) [4]. 
Post-gadolinium enhancement as commonly seen in pilocytic astrocytomas is often minimal 
or absent in DIPG (Figure 1E) [19, 20]. With an average molecular weight of 545 kDa, gado-
linium largely exceeds the penetration cut-off of the blood brain barrier (BBB) (400–600 Da) 
with limited contrast enhancement in DIPG suggesting a largely intact BBB [14, 21]. Other 
MRI features typical of DIPG include ventral involvement of the pons and encasement of the 
basilar artery (Figure 1F) [5].
4.2. New imaging techniques
4.2.1. MR spectroscopy (MRS)
MRS provides a measure of brain chemistry. The most prominent peaks in the brain spec-
trum on Proton MRS are N-acetyl aspartate (NAA), creatine, and choline. NAA is a neuronal 
marker which is usually decreased in tumors. Choline is associated with the metabolism of 
membrane turnover and is generally increased in tumors. In DIPG, MRS shows a modest 
increase in choline levels and a decrease in NAA levels [14]. Additionally, peaks from lactate 
and mobile lipids are often elevated [11]. The abnormalities in these normally occurring brain 
metabolites may provide insight into the biology of DIPG and become invaluable tools in 
DIPG radiodiagnosis.
4.2.2. Perfusion and diffusion techniques
Some of the newer perfusion and diffusion MRI techniques are being tested in prospective trials 
and although not a standard for DIPG diagnosis currently, may prove beneficial in the future. 
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Figure 1. T1-weighted pre-contrast sagittal (A) and axial (B) MRI pictures showing poorly marginated, expansile and 
hypointense pontine mass. It is hyperintense onT2-weighted/FLAIR sagittal (C) and coronal (D) images. (E) There is 
minimal post-gadolinium enhancement. (F) Basilar artery encasement by DIPG (black arrow).
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MR perfusion measures regional blood volume and flow reflecting the vascular nature of neo-
plasms [22]. Serial changes in tumor vascularity may be useful to monitor the effectiveness of 
therapy. Diffusion tensor imaging may provide visualization and quantitative characterization 
of the major white matter pathways in DIPG [23, 24]. This superior delineation between tumor 
and normal brain compared to the conventional MRI techniques may prove useful, especially 
to perform biopsies and obtain DIPG samples. Specific MRI sequences, including single-voxel 
spectroscopy (SVS), multi-voxel MRS and dynamic susceptibility contrast (DSC) MRI may 
help in predicting short or long survival interval from diagnosis in patients with DIPG [25].
4.2.3. Molecular drug imaging
Imaging of radiolabeled drugs like monoclonal antibodies and tyrosine kinase inhibitors can 
be achieved by using PET technology [26]. A recently introduced PET imaging technique 
of zirconium-89 (89Zr)-labeled bevacizumab in children with DIPG demonstrated consider-
able inter-and intra-tumoral heterogeneity in drug delivery [27]. Therapeutic potential and 
toxicity both can be quantified by such non-invasive, in patient techniques of tumor imag-
ing and drug distribution [28]. Thus, these newer imaging modalities provide quantitative 
physiologic and functional information to complement the anatomic visualization provided 
by conventional imaging. However, these techniques need further validation and have yet to 
impact treatment decisions [11].
5. Pathology
Grossly, DIPG tumors tend to spread contiguously, extending to involve the midbrain, 
medulla, and cerebellar peduncles [29, 30]. Up to 20% of patients are reported to have lepto-
meningeal disease at diagnosis [31] and almost 56% have spinal metastases or leptomeningeal 
dissemination at the time of recurrence or autopsy [32, 33]. Microscopically, the majority of 
tumors resemble malignant gliomas in other regions. Tumor cells appear relatively small, 
with prominent cytoplasmic intermediate filaments and cell processes [34]. Tumor cells per-
vade normal cells (Figure 2A and B), diffusely expanding the pons and distorting, displacing 
and destroying nerve fiber tracts that normally course through it [34]. Anaplasia, increased 
mitotic activity (Figure 2C), tumor necrosis (Figure 2D) and vascular proliferation (Figure 2E) 
are often present [5]. A histopathological hallmark is perineuronal satellitosis in which collec-
tion of tumor cells are found around pontine neurons [35]. DIPG is histologically classified as 
fibrillary astrocytoma, World Health Organization (WHO) Grades II–IV [36] but the prognosis 
is not associated with histological grade [37, 38]. There can be marked intratumoral heteroge-
neity with a high proportion of samples showing focal areas of WHO grade I phenotype [39].
5.1. Diffuse midline glioma, H3K27M-mutant
In the latest WHO classification, DIPG have been grouped with other midline gliomas 
(thalamus, spinal cord) forming a new diagnostic entity. These tumors are characterized by a 
Diffuse Intrinsic Pontine Glioma
http://dx.doi.org/10.5772/intechopen.78578
39
Figure 2. Histologic features of DIPG. Tumor infiltrating medullary neurons, H & E 100× (A) and 200× (B). (C) Tumor 
showing mitotic figures, H & E 400×. (D) Tumor/necrosis interface showing pseudo-palisading tumor necrosis. (E) 
Exuberant tumor-associated microvascular proliferation. (F) Tumor cells showing positive nuclear H3K27 M staining 
with sparing of the endothelial nuclei of admixed blood vessels H3K27 M 200×. (G) Loss of staining of tumor cell nuclei 
with the trimethylated antibody with retained staining in the endothelial cells, H3K27me3 200×. Images courtesy of Dr. 
Jason Dyke (Royal Perth Hospital, Australia).
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specific histone mutation (H3K27 M) and are called diffuse midline glioma, H3K27M-mutant 
[40]. A mutation-specific antibody can be used to detect this mutation on immunohistochem-
istry (Figure 2F).
6. The role of biopsy in diagnosis
Prior to the routine MRI use, it was estimated that up to 15% of patients diagnosed with DIPG 
had a non-glial tumor or non-tumor process [41, 42]. The role of surgical intervention was con-
troversial and, in some centres, biopsy procedures were frequently undertaken for histological 
confirmation. Although it is not 100% specific, with the wide availability in the early 1990s 
MRI became the modality of choice for DIPG diagnosis. Biopsy confirmation was thought 
to be an unnecessary risk as it did not alter the management [43]. The lack of clear biopsy 
benefit combined with improved diagnostic imaging capabilities led to MRI scans becoming 
the diagnostic standard of care for DIPG in the United Sates [18, 44]. More recently, there has 
been a renewed interest in performing stereotactic biopsies in patients with DIPG [45]. In 
France, biopsies were routinely performed with minimal morbidity and high diagnostic yield 
[46], nonetheless, it was not a common practice. The increase in the available DIPG tumor 
samples has yielded valuable data toward improving our understanding of the biology of 
DIPG [45, 47, 48]. Some of the identified biologic markers have been shown to correlate with 
progression-free survival (PFS) and may be useful to stratify patients in future clinical trials 
[49]. Considering the potential for new diagnostic and therapeutic methods combined with 
low morbidity associated with surgical procedures [50], the option of biopsy is being recon-
sidered and may eventually be included as part of the routine diagnostic evaluation for DIPG 
[51]. The second Consensus Conference on Pediatric Neurosurgery recommended biopsy in 
DIPG to ascertain biological characteristics to enhance understanding and targeting of treat-
ment, especially in the setting of clinical trials [52]. Biopsy from a single area may not be rep-
resentative of the entire tumor [53] but it may still provide important molecular information.
7. Treatment
More than 250 clinical trials in the last three decades have failed to improve the poor outcome 
of DIPG [20]. Due to the location it is not amenable to the surgery and chemotherapy agents 
are yet to show any response. Radiation therapy remains the standard of care at present. The 
barriers to achieve a cure for DIPG may include the inability of the surgical resection, drug 
delivery difficulties secondary to the blood-brain barrier (BBB) and intra- and inter-tumoral 
heterogeneity in the identified molecular aberrations [54].
7.1. Surgery
Surgical resection of DIPG is not feasible due to the presence of vital structures where the 
tumor is located. Rarely, surgical intervention like ventriculoperitoneal shunt or endoscopic 
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third ventriculostomy may be necessary to relieve raised intracranial pressure secondary to 
hydrocephalus. Many patients benefit from steroids which help by reducing peritumoral 
edema.
7.2. Radiation therapy (RT)
Conventional RT in a dose of 54–60Gy over a 6 week period is commonly utilized in the 
treatment of DIPG [9]. Temporary improvement or stabilization of symptoms is seen in 70% 
of patients, but almost all patients have progressive disease. The mean progression-free sur-
vival (PFS) is 5.8 months with radiotherapy and 5 months without it [4]. As RT is effective 
temporarily, non-conventional doses and delivery schedules were investigated. In hyperfrac-
tionated RT, the total dose is divided into smaller doses and given more than once a day. 
Hyperfractionated RT in the form of 1Gy twice a day, to the total dose of 72Gy failed to 
improve the outcome [37]. Hypofractionated RT is given over a smaller period of time than 
standard RT by dividing the total RT dose into larger doses and treatments given once a day 
or less often. Studies investigating the role of hypofractionated RT with 39Gy [55] or 45Gy [56] 
delivered over 3 weeks have revealed similar survival outcomes, but may be more acceptable 
to fami9lies due to the shorter delivery times.
7.3. Chemotherapy
Various chemotherapy and targeted agents have been used to potentiate the beneficial effects 
of RT. These agents were combined before, with, and after RT without much success [9, 10].
7.3.1. Intensive chemotherapy
Chemotherapy combinations used with RT in the setting of phase I–III clinical trials. These 
include lomustine, vincristine and prednisone [41], cisplatin, etoposide, vincristine, ifos-
famide and oral valproic acid [57], myeloablative thiotepa, isotretinoin and vinorelbine [58] 
and multiple other agents at relapse [59]. One trial evaluated the role of preradiation chemo-
therapy [60]. The outcome was uniformly poor.
7.3.2. Radiosensitizing agents
i. Temozolomide (TMZ): TMZ is an alkylating prodrug which is converted into its active 
metabolite monomethyl 5-triazeno imidazole carboxamide. TMZ causes DNA damage 
by alkylating O6-guanine, N7-gaunine and N3-adenine resides [61]. Due to its proven effi-
cacy in high grade gliomas, low toxicity and radiosensitization potential, temozolomide 
was trialed to potentiate RT efficacy without much success [8, 62, 63]. Addition of lomus-
tine to adjuvant temozolomide [64] was not beneficial. O6-methylguanine DNA meth-
yltransferase (MGMT) contributes to TMZ resistance by repairing alkylated O6-guanine 
nucleotides. But this does not appear to be the cause of TMZ resistance as MGMT is 
not expressed in DIPG [47]. However, 3-methylpurine-DNA glycosylase (MPG), enzyme 
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responsible for repair of N7-gaunine and N3-adenine nucleotides, and its ATM-dependent 
regulation may play a role in TMZ resistance in DIPG [65]. A recently closed phase II 
study stratified patients to receive TMZ and erlotinib based on MGMT methylation and 
EGFR expression status [66].
ii. Topotecan: topotecan acts as a radiosensitizing agent by stabilizing the DNA topoisomer-
ase I complex, interfering with DNA replication and DNA repair. Concurrent administra-
tion of topotecan with RT was found to be ineffective [67, 68].
iii. Other radiosensitizing agents like motexafin-gadolinium [69] and carbogen [70] also 
showed similar poor results.
8. Biology
More than 250 therapeutic clinical trials including several targeted agents have not improved 
the dismal prognosis of DIPG [10]. The reason for this, at least in part, has been attributed 
to our lack of understanding of the biology of this disease. More has been published on the 
biology and pathophysiology of DIPG in the past 10 years than in all prior years combined [5]. 
A more recent and significant achievement in DIPG research is sample collection at autopsy. 
This has provided invaluable insights into understanding of the biology [71, 72]. Both autopsy 
and biopsy samples have allowed development of in-vitro (neurospheres) and in-vivo models 
(allograft and xenograft) [73–75].
8.1. Cell of origin
Pontine precursor-like cells (PPC), found in the ventral pons region, which are positive for the 
markers for the primitive neural precursor cells, nestin and vimentin, are postulated as the candi-
date cell of origin for DIPG [35]. Approximately half of PPC also expressed Olig2, a transcription 
factor which is associated with oligodendroglial precursors. This cell type was morphologically 
distinct from the nestin positive cells seen in the dorsal brainstem. PPC are present in all ventral 
brainstem structures during infancy and wane by 2 years of age. The ventral pontine and med-
ullary nestin+ cells show a second peak at 6 years, corresponding to the age of presentation of 
DIPG. Thus, temporal and spatial distribution of these cells correlates closely with the incidence of 
DIPG suggesting that tumors arise secondary to dysregulation of a postnatal neurodevelopmen-
tal process [35]. Expression of SOX2, a transcription factor with activity during embryogenesis, 
and Olig2 in another model supports the disordered neurodevelopmental origin of DIPG [76].
8.2. The genomic landscape
DIPG biopsy and autopsy samples have undergone extensive genomic profiling and major 
breakthroughs have been achieved in identifying key oncogenic pathways [77]. The drivers 
for DIPG tumorigenesis include epigenetic changes, gene mutations, deletions or overexpres-
sion and chromosomal number changes.





The DNA is packaged by histone proteins into a chain of nucleosomes which are the basic 
building blocks of the chromatin fiber [78]. In a single nucleosome, 147 base pairs (bp) of DNA 
wrap around histone octamers containing two copies each of histones H2A, H2B, H3 and H4 
[79]. The N-terminal ends of histones containing lysine (K) and arginine (R) residues are post-
translationally modified by acetylation or methylation and regulate DNA repair, replication 
and transcription. The histone H3 family consists of a number of related proteins. Histone 
H3 isoforms H3.1 and H3.2 (also called as canonical H3) help in packaging newly replicated 
DNA. While H3.3 can function much the same as canonical H3 as a core part of the nucleo-
some, it is also deposited into transcriptionally active regions to replace histones lost during 
processes disrupting nucleosomes [80].
8.3.1.1. H3 mutations and DIPG
8.3.1.1.1. H3K27M mutations
H3F3A and H3F3B produce identical H3.3 proteins whereas HIST1H3B is one of the many 
genes encoding H3.1 [81, 82]. Distinct and recurrent mutations in H3 have been implicated 
in 70–80% of pediatric gliomas [83]. Lysine to methionine missense mutation at position 27 
(K27M) was present in 78% of DIPG patients, with most of these mutations in H3F3A and up 
to 25% in HIST1H3B [84, 85]. H3K27M mutations are restricted to the midline structures [86] 
and H3.1 and H3.3 mutations involve two different oncogenic pathways resulting in distinct 
clinicopathological variants. H3.1 mutated tumors are exclusively linked to DIPG and exhibit 
a mesenchymal/astrocytic phenotype, a pro-angiogenic/hypoxic signature and are co-segre-
gated with ACVR1 mutations. Clinically, these tumors are less aggressive when compared to 
H3.3 mutant tumors, metastasize less frequently and respond better to radiation therapy (RT) 
with a median overall survival (OS) of 15 months. H3.3 mutated tumors are located in the 
midline structures including the brainstem, thalamus and spinal cord. They have a proneu-
ral/oligodendroglial phenotype, a pro-metastatic gene expression signature with PDGFRA 
activation. They behave more aggressively, responding poorly to RT with a median OS of 
9 months and metastasize more frequently [87]. The gain-of-function H3K27M alterations are 
exclusive to pediatric high-grade gliomas and any H3 mutation is associated with a dismal 
outcome but identification of a specific mutation may help in developing specific therapeutic 
targets.
8.3.1.1.2. G34R/V mutations
H3F3A mutations encoding a glycine 34 to arginine or valine G34R/V comprise a smaller 
proportion of H3.3 mutations [88]. G34R/V mutations are seen in cerebral hemispheres of 
slightly older patients (9–42 years) as compared to K27M mutations (5–29 years) [86, 88, 89].
K27M and G34R/V mutations are mutually exclusive and heterozygously expressed, with one 
wild-type H3F3A allele [89].
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8.3.1.1.3. Other novel mutations
H3F3A mutation resulting in lysine-to isoleucine substitution at K27 has been rarely seen in 
DIPG [87]. A mutation in the gene encoding the H3.2 variant, HIST2H3C, resulting in a novel 
K27 M mutation has been described [87].
8.3.1.2. Downstream effects of H3 mutations and gliomagenesis
8.3.1.2.1. K27 M mutations
K27M (and to a lesser extent K27I) is the only amino acid substitution which can ablate tri-
methylation (H3K27me3) [90]. The mutant H3K27M binds to the enhancer of zeste homolog 2 
(EZH2) component of PRC2 interfering with methyltransferase activity of EZH2 which results 
in generalized hypomethylation. The downstream effect is derepression of targets of PRC2, 
upregulation of gene expression and gliomagenesis [91]. In addition, K27M mutation contrib-
utes to altered cell cycle control, inhibition of autophagy pathways and potentially increased 
resistance to radiotherapy [92]. Even though the mutant histone forms only 3.6–17.6% of the 
total cellular H3 pool, there is a near-absolute loss of H3K27me3. This represents a trans-
dominant-negative effect across all three isoforms of the wild-type H3 protein [90, 91, 93, 94]. 
However, the exact role of H3K27M in DIPG tumorigenesis remains unknown as it does not 
induce the tumors on its own in vivo [95]. One of the postulates of gliomagenesis is H3.3 K27M 
and G34R/V acting as driver mutations followed by a second hit by another mutation like 
TP53, PPM1D, ACVR1 or PI3KR1 [83, 95, 96].
In summary, H3K27 mutations have a great significance irrespective of whichever histone H3 
variant (H3.1-HIST13B, H2-HIST2H3C and H3.3-H3F3A) is targeted and will result in loss of 
H3K27me3 and development of DIPG.
8.3.1.2.2. G34R/V mutations
The role of H3.3G34R/V in gliomagenesis is less clear. It may act by disrupting K36me3 levels 
and activating potential oncogenes [90, 93]; inducing MYCN upregulation [97, 98] and dis-
rupting interaction between H3.3 and ATRX/DAXX leading to aberrant deposition of H3.3 
near telomeric regions and leading to alternate lengthening of telomerase [88, 89, 99].
8.3.1.3. Co-mutations associated with H3 mutations in DIPG
Other mutations associated with H3K27M mutation include α thalassemia/mental retarda-
tion syndrome X-linked (ATRX) or death-domain associated protein (DAXX) (30%), TP53 
(60%) and NF-1, PDGFRA, BRAF, KRAS, and FGFR1 at lower frequencies [88, 99, 100]. G35R/V 
mutations coexpress with mutations in TP53, ATRX/DAXX and PDGFRA [83].
8.3.1.4. Mutations of chromatin modifiers
Chromatin writers or erasers are the enzymes which catalyze the post-translational modi-
fications of histone tails like methylation, acetylation and ubiquitylation of lysine residues, 
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phosphorylation of serine or threonine residues and methylation of arginine residues. The 
effector proteins called readers are recruited to the chromatin by the resultant histone code 
which helps in localization of functional complexes that affect transcriptional regulation 
[101]. Numerous recurrent mutations are observed in chromatin writers, erasers, readers and 
remodelers in DIPG and other tumors [102].
The discovery of histone mutations which are present in up to 80% of DIPG is one of the 
most remarkable breakthroughs in terms of understanding DIPG biology and identification 
of actionable targets [90, 92, 99].
8.3.2. Polycomb repressive complex (PRC) abnormalities
Polycomb group proteins remodel chromatin enabling epigenetic silencing of genes. There 
are two main Polycomb group complexes found in mammals-PRC1 and PRC2. PRC1 cata-
lyzes the monoubiquitylation of histone H2A and PRC2 catalyzes the methylation of H3K27 
[103]. Some PRC1 complexes also act independent of enzymatic activity to regulate gene 
expression by compacting chromatin [104]. PRC1 functions downstream of PRC2 by bind-
ing specifically to H3K27me3 [103]. By inducing such sequential histone modifications, PRC1 
and PRC2 achieve stable silencing of gene expression [105]. Dysregulation of PRC and its 
downstream targets has been implicated in many cancers [83]. B cell-specific Moloney murine 
leukemia virus integration site 1 (BMI-1) is a component of PRC1 complex. It was found to 
be highly expressed in DIPG tumor cells and its downregulation inhibited various cellular 
processes like cell proliferation, cell cycle signaling, telomerase expression and activity, and 
cell migration [105].
8.4. Gene abnormalities
Molecular profiling of DIPG samples has provided new insights [61]. In the past, candidate 
gene approaches were utilized to identify gene abnormalities associated with adult high-
grade gliomas (HGG) [106]. Although, these studies were limited in defining the biology 
of DIPG due to their small numbers, they still highlighted some differences between adult 
HGG and DIPG. Recently, studies performed with next-generation sequencing approaches 
have confirmed that DIPG are molecularly distinct from adult HGG and non-DIPG pediatric 
HGG [18]. The current technologies utilize whole-genome sequencing (WGS), whole-exome 
sequencing (WES), and RNA-sequencing in addition to copy number, gene expression, and 
methylation profiles and histopathology.
8.4.1. Mutational burden of DIPG compared to other tumors
The genomic signatures of the most pediatric HGG are complex and involve significant copy 
number alterations (CNAs), single nucleotide variants (SNVs) and structural variants [107–
109]. HGG have a higher mutation burden than many other pediatric cancers but it is still 
lower than common adult cancers [77]. HGG commonly show structural variants like simple 
rearrangements and abnormalities caused by chromothripsis [84]. But there is a wide range 
of genomic complexity in pediatric HGG. At one end of the spectrum is infant non-brainstem 
HGG (NBS-HGG) arising in children less than 3 years old. These tumors have significantly 
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lower mutation burden [84]. At the other end of the spectrum are HGG from patients with 
inherited mutations in mismatch repair genes. Germline mutations in tumor suppressor 
genes like TP53 and neurofibromin 1 (NF1) predispose to the development of HGG [110]. The 
hypermutated tumors arising in the context of these germline mutations show a very high 
number of somatic SNVs; these may be more than 100-fold higher than in 95% of pediatric 
HGG [84]. DIPG show similar mutation burden as other pediatric HGG and their genomic 
complexity is indicative of multiple genetic mechanisms generating numerous mutations 
which provide the tumor with diverse potential pathways to therapeutic resistance [77].
8.4.2. Abnormalities of cellular proliferation pathways
8.4.2.1. Bone morphogenetic protein (BMP) signaling and ACVR1 mutations
ACVR1, also known as ALK2 encodes the serine kinase, Activin receptor type 1 A (ACVR1) 
[111]. It is a type 1 BMP receptor which belongs to the mammalian TGF-β signaling fam-
ily [112]. ACVR1 binds to a diverse set of ligands, including TGF-β, activins and multiple 
BMP [113]. ACVR1 is essential for signaling and after ligand it is phosphorylated by ACVR2 
with formation a stable ACVR1/2 complex [114]. This results in the phosphorylation and 
activation of growth promoting genes through SMAD transcription factors [77]. ACVR1 
mutations are constitutionally activating, leading to increased expression of activin signal-
ing targets ID1 and ID2 [115].
8.4.2.1.1. ACVR1 mutations and DIPG
Germline ACVR1 mutations cause the congenital malformation syndrome fibrodysplasia 
ossificans progressive (FOP) [116]. Seven somatic mutations of this gene have been identi-
fied in 13–32% of DIPG samples leading to either ligand-independent kinase activation or 
gain-of-function effects [84, 111, 112, 115]. However, there is no increased cancer risk in FOP 
despite having similar germline mutations as those seen in DIPG which suggests that ACVR1 
mutations on their own are not tumor initiating and lead to DIPG only in the presence of other 
mutations [77, 116].
8.4.2.1.2. ACVR1 co-mutations
ACVR1 mutant tumors commonly co-segregate with HIST1H3B mutations [115]. ACVR1-
HIST1H3B co-segregating tumors do not show TP53 loss or PDGFRA amplifications but 
around 60% have mutations in the PI3K signaling pathway [114].
8.4.2.1.3. Clinical implications
ACVR1 mutations signify a distinct subset of DIPG patients. They occurred more frequently in 
females (F:M ratio of 1.75:1) and are associated with younger age and longer survival (median 
OS of 14.9 months) [84, 111]. There was a significant pharmacologic inhibition of ACVR1 by a 
selective ALK2 inhibitor, LDN-193189, leading to dose-dependent cytotoxicity across all the 
tested DIPG cell lines [111]. Due to its role in DIPG pathogenesis and targetable potential, 
ACVR1 inhibition represents a novel therapeutic option.
Diffuse Intrinsic Pontine Glioma
http://dx.doi.org/10.5772/intechopen.78578
47
8.4.2.2. Receptor tyrosine kinase (RTK) pathway
RTKs are transmembrane protein receptors containing intrinsic enzymatic activity. Their 
ligands include growth factors, hormones and cytokines [117] and they play an critical role in 
mediating key signaling pathways involving cell proliferation, differentiation, survival and 
migration [118]. The human RTK family has 20 subfamilies and 58 known members including 
platelet-derived growth factor receptors (PDGFR), epidermal growth factor receptors (EGFR) 
and fibroblast growth factor receptors (FGFR) [118–120]. Upon ligand binding, the RTKs are 
activated leading to signal transduction to the nucleus and subsequent protein transcription. 
This is achieved by downstream activation of various RTK substrates like mitogen-activated 
protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K) [121].
8.4.2.2.1. RTK pathway aberrations and DIPG
Amplifications and mutations in components of RTK-RAS-PI3K pathway are seen in up to 
60% of DIPG [18]. The most common affected component is PDGFRA. Other abnormalities 
involve AKT1, AKT3, c-MET, epidermal growth factor receptor (EGFR), erythroblastic leuke-
mia viral oncogene homolog-4 (ERBB4), hepatocyte growth factor, Kirsten rat sarcoma viral 
oncogene homolog (KRAS), PIK3CA, PIKC2G, PIK3R1, PTEN, insulin-like growth factor 2, 
and insulin-like growth factor receptor [18, 45, 53, 111].
8.4.2.2.1.1. PDGFRA amplifications
Whole-genome profiling of DIPG tumors have identified recurrent amplifications of PDGFA 
and PDGFRA with overexpression of PDGFR-α in 28–50% tumors [47, 48, 122, 123].
8.4.2.2.1.2. PDGFRA mutations
Somatic activating mutations including missense mutations and in-frame deletions and inser-
tions were identified in 4.7% DIPG tumors and were found to be oncogenic in vivo [124]. 
Concurrent amplification was seen in 40% of tumors with mutations and 60% had heterozy-
gous mutations [124]. Similar mutations were identified in other studies in 8.8–25% samples 
[54, 123]. Downstream activation of the PDGFR pathway has been shown by phospho-mam-
malian target of rapamycin (m-TOR) immunopositivity [47] as well as activation of MAPK and 
PI3K pathways [124]. PDGFR-α is expressed by the oligodendrocyte precursor cell derived 
from the candidate cell of origin PCC [35] and hence the precursor cell may be responsive to 
PDGF. Also, human DIPG cell culture yield was better after the addition of PDGF [35] and 
upregulation of PDGF pathway was associated with dorsal pontine glioblastoma in mouse 
models [125, 126].
8.4.2.2.1.3. EGFR aberrations
EGFR immunopositivity and gene amplification were seen in about 27% [47] and 7–9% [48] 
of cases respectively.
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8.4.2.2.2. RTK pathway co-mutations in DIPG
PDGFRA gains and amplifications co-segregate with H3.3 mutations [88, 99] and TP53 muta-
tions [124].
8.4.2.2.3. Clinical significance
RTK signaling dysregulation, particularly PDGFR pathway either overexpression or muta-
tion, may have an important role in the pathophysiology of DIPG and provide therapeutic 
targets [47]. Identification of PDGFRA mutations may be beneficial in developing targeted 
therapies. But some particular mutations like PDGFR D842V in the gastrointestinal stromal 
tumors confers resistance to imatinib [127]. Others may have only cytostatic effects so they 
may not be effective on their own [124].
8.4.2.3. MYC and MYCN aberrations
MYCN proto-oncogene is a member of the MYC family encoding the protein MYCN. MYCN 
plays a critical role during embryogenesis and is involved in cellular proliferation and dif-
ferentiation [128]. MYCN amplification is seen in DIPG [84, 92, 99] and is associated with 
hypermethylation, high-grade histology and chromothripsis on chromosome 2p [115]. MYCN 
amplifications are transcriptional regulators that affect the epigenetic landscape by enhanc-
ing gene expression across the whole genome [84]. MYCN pathway maybe induced by 
H3.3 K27 M [99] or H3.3G34V [83, 102] but may act independent of H3 mutations [92].
8.4.2.4. Hedgehog (Hh) signaling
Hh signaling pathway plays a major role in regulation of developmental processes like cell 
proliferation, cell differentiation, tissue polarity and stem cell maintenance. Aberrant activa-
tion of Hh pathway has been implicated in the pathogenesis of cancers like medulloblas-
toma. No structural mutation involving this pathway resulting in the development of DIPG 
has been identified so far. However, in pre-clinical murine models [35] upregulation of Hh 
pathway activity resulted in ventral pontine hyperplasia. Hh pathway is essential for the nor-
mal development of PPC in humans. Also, Hh pathway activation stimulates and blockade 
reduces the self-renewal capacity of DIPG neurosphere cells. These findings indicate that 
Hh signaling, which drives the development of neural precursors in the ventral pons, may 
play a role in tumor formation in a subset of DIPG. Patients with Gorlin syndrome, a genetic 
entity occurring secondary to unregulated Hh activity, usually do not develop DIPG [35]. So, 
in addition to unregulated Hh pathway activity, a second “hit” may be necessary for DIPG 
transformation. Hh signaling role in the pathogenesis of DIPG was further investigated in a 
study [92] which identified upregulation of Hh signaling. DIPG samples showed upregula-
tion of Patched (PTCH) and nuclear translocation of Glioma Associated Oncogene 1 (GLI1); 
both PTCH and GLI1 are key Hh pathway molecules. In summary, Hh pathway may play a 
significant role in DIPG tumorigenesis by stimulating PPC and transforming them into poten-
tial DIPG cancer stem cells (CSC).
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8.4.3. Abnormalities of cell cycle regulation pathways
8.4.3.1. TP53 pathway
The TP53 pathway is a complex network of genes which respond to diverse internal and 
external stress signals and have an impact on the normal cellular homeostasis [129]. The p53 
protein is activated by stress signals transmitted as post-translational modifications leading to 
apoptosis [130]. In addition, the TP53 pathway produces proteins which aid directly in DNA 
repair processes and alter cellular environment enabling inter-cellular communication [131]. 
In the critical role of safeguarding the genomic integrity, it functions as a tumor suppression 
pathway [132]. TP53 is the most commonly mutated gene found in a broad variety of human 
cancers [129, 133].
8.4.3.1.1. TP53 mutations and DIPG
TP53 mutations are commonly found in DIPG with the reported incidence between 9 and 77% 
[45, 99]. They are more common in higher grade histology tumors (grades III and IV) [53]. About 
50% of TP53 wild-type grade II DIPG show presence of PPM1D mutations [134]. PPM1D is an 
oncogene associated with cancers like neuroblastoma [135] and lung cancer [136] which codes for 
wild-type p53-induced phosphatase 1D (WIP1). WIP1 is a negative regulator of TP53 as it inacti-
vates p53 and promotes termination of stress-induced responses. So PPM1D mutations have the 
same functional significance as TP53 mutations [137]. PPM1D and TP53 mutations are mutually 
exclusive and may ultimately lead to dysregulated homeostasis and tumorigenesis [134].
8.4.3.1.2. TP53 co-mutations in DIPG
TP53 mutations more commonly co-segregate with H3.3 K27 M than H3.1 K27 M [112] and 
frequently occur in the setting of PDGFRA aberrations [124].
8.4.3.2. The RB pathway
Cyclins and cyclin-dependent kinases (CDKs) control the G1/S transition of the cell cycle [138]. The abnormalities involving these regulators observed in DIPG include cyclin-dependent 
kinase inhibitor 2A or 2B (CDKN2A or CDKN2B) deletions [48, 122] and CDK4, CDK6 or cyclin 
D1 (CCND1), CCND2, and CCND3 amplifications [48, 122, 139].
8.4.3.3. Aurora kinase pathway
Aurora kinase family include three highly homologous serine/threonine kinases required 
during mitosis and which are linked to many cancers [140]. AURKB forms the catalytic com-
ponent of the chromosomal passenger complex (CPC) which plays a critical role during mito-
sis [141]. Almost 70% of DIPG have demonstrated overexpression of AURKB [142].
8.4.3.4. WEE1 kinase pathway
WEE1 kinase is an important part of G2 checkpoint. DIPG cells, unlike normal cells, have aber-rations in genes regulating the G1 checkpoint, including TP53, MDM2, CDKN2A, and ATM 
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[122, 133, 143] causing a dysfunctional G1 arrest. So, these cells rely heavily on G2 checkpoint to repair DNA damage caused by irradiation. WEE1 protein is significantly overexpressed in 
post-mortem DIPG samples [73]. Abrogation of the G2 checkpoint achieved by WEE1 kinase inhibition pushes DIPG cells with unrepaired DAN damage into mitotic catastrophe resulting 
in cell death.
8.4.3.5. Poly (ADP-ribose) polymerase (PARP)-1 abnormalities
PARP-1 is a nuclear protein involved in the DNA damage repair processes [144]. PARP-1 
activity provides an escape mechanism for cancer cells to avoid apoptosis and its overexpres-
sion may be associated with temozolomide and radiation resistance [47]. Gain of PARP-1 is 
seen in DIPG tumors and provides a potentially targetable therapeutic option [47].
8.5. Chromosomal number abnormalities
Copy number abnormalities (CNAs) reported in DIPG include gain in chromosomes 1q, 2q, 
8q, 9q, 7p/7q and loss in chromosomes 16q, 17p, 20p, 21q, 10q and 4q [47, 48, 122, 123, 139, 145]. 
The CNAs may represent the initial mutations responsible for DIPG tumorigenesis as well as 
the treatment effect.
8.6. Immune checkpoint abnormalities
8.6.1. B7-H3 abnormalities
B7-H3 or CD276, a member of the B7-CD28 family, is a type I transmembrane glycoprotein [146]. 
Many malignant neuroectodermal tumors including adult HGG over-express B7-H3. B7-H3 
was found to be overexpressed in a small panel of DIPG samples obtained at autopsy [147]. 
A monoclonal antibody 8H9 recognizes it and binds specifically to the tumor cells [148, 149] 
enabling therapeutic cell selectivity. B7H3 was targeted safely in the salvage therapy of stage IV 
neuroblastoma using intrathecal 131I-8H9 [150].
8.7. Tumor microenvironment abnormalities
Therapies targeted at intrinsic cellular pathways have yielded poor results in DIPG. Tumor 
microenvironment plays a vital role in tumorigenesis and progression, so studies have looked 
into investigating microenvironment alteration for better results.
8.7.1. Neuroligin-3 (NLGN3) role
Neuroligin-3 (NLGN3) is a synaptic adhesion molecule which is cleaved from neurons and 
oligodendrocyte precursor cells via the ADAM10 sheddase and released into the tumor 
microenvironment. This important neuronal activity promotes many types of brain can-
cers including DIPG, pediatric and adult HGG and anaplastic oligodendroglioma. NLGN3 
release activates oncogenic pathways like focal adhesion kinase activation resulting in the 
downstream PI3K-mTOR pathway induction. This in turn causes upregulation of several 
synapse-related genes resulting in the proliferation of glioma cells [151]. HGG glioma growth 
in xenograft models was blocked by ADAM10 inhibitors by preventing NLGN3 release into 
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the tumor microenvironment. Similarly, patient-derived orthotopic xenografts fail to grow in 
Nlgn3 knockout mice [152].
8.7.2. Pleiotrophin (PTN) role
PTN is a growth factor secreted by neural precursor cells in the lateral ventricle subventricu-
lar zone (SVZ). It has an important role in normal neurodevelopment, plasticity and regenera-
tion. PTN acts as a glioma chemoattractant. Through autocrine/paracrine actions, it activates 
Rho/Rho kinase (ROCK) signaling pathway enabling migration of DIPG cells to the SVZ [153].
9. DIPG subgroups
Proteomic, methylation and mRNA analyses have identified interesting subgroups of DIPG.
PDGFRA amplification is seen in association with H3.3 mutation and ACVR1 mutation is 
mainly seen in H3.1 mutant tumors [87, 115].
Upregulation of N-Myc and Hh signaling pathways [92].
Upregulation of N-Myc (H3 wild-type), silent genome and H3K27 M [115].
Mesenchymal transition with stem cell-like phenotype and oligodendroglial differentiation 
and PDGFRA amplification/mutation.
10. Novel therapeutic approaches
10.1. Molecularly targeted agents
10.1.1. RTK-RAS-PI3K pathway
Given DIPG tumors show aberrant activation of growth factor receptor-mediated signal 
transduction pathways, using drugs targeting these pathways is a rational approach. In-vitro 
studies confirmed the efficacy of tyrosine kinase inhibitors (TKI) like dasatinib in reducing 
tumor proliferation and inhibition of PDGFRA activity [154]. Phase I studies of PDGFR path-
way inhibition by imatinib [155] and dasatinib [156], VEGFR2 inhibition by vandetinib [156, 
157], EGFR inhibition by gefitinib [158] and erlotinib [49] revealed the safety of using these 
drugs in children and provided the doses for phase II studies. Temsirolimus is an mTOR 
inhibitor [159] and its combination with perifosine, an Akt inhibitor, was shown to be safe and 
feasible in a phase I study in children with recurrent/refractory solid tumors including DIPG 
[160]. This study tested the hypothesis of dual targeting of PI3K-Akt–mTOR pathway. Phase 
II studies of multi-tyrosine kinase inhibitor sunitinib [161] and farnesyl transferase inhibitor 
tipifarnib, which inhibits farnesylation of Ras, [162] did not show activity. BIOMEDE, a phase 
II study, is stratifying patients based on overexpression of EGFR and/or loss of PTEN follow-
ing diagnostic biopsy. The patients are randomized or assigned to different treatment arms 
with erlotinib, everolimus and dasatinib [163].
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10.2. Epigenetic modifying agents
Histone deacetylases (HDAC) regulate the histone acetylation in nucleosomes, which medi-
ates changes in chromatin conformation, leading to gene expression regulation [164]. HDAC 
gene mutations, downregulation and altered expression are linked to tumorigenesis. Histone 
deacetylase (HDAC) inhibitors modify histone activity to increase expression of previously 
silenced genes thereby leading to cell death [165]. Panobinostat is a multi-HDAC inhibitor 
which increases global H3 acetylation and H3K27 M methylation and reduces oncogene 
expression. Panobinostat-induced polyacetylation of the H3 N-terminal tail has been shown 
to reverse PRC2 inhibition caused by K27 M and rescue the H3K27 hypomethylation pheno-
type [166]. Panobinostat has shown promising results in in vitro [164] and some in vivo [167] 
studies although a narrow therapeutic index causing dose limiting toxicities at the required 
antitumor concentrations being the likely reason for lack of efficacy [164]. Its efficacy was 
further enhanced by histone demethylase inhibitor GSK-J4 which increase H3K27me3 [168]. 
DIPG patients showed no objective responses to single agent vorinostat in a phase I clinical 
trial [169]. Vorinostat is currently being investigated in combination with temsirolimus and 
RT in DIPG in a phase I trial [170]. Pediatric Brain Tumor Consortium (PBTC) is undertaking 
a phase I trial of single agent Panobinostat in patients with DIPG [171].
10.3. Targeting cell cycle regulation
DIPG tumors contain cell cycle regulatory gene abnormalities like amplification of D-type 
cyclins and CDK4/6 or loss of Ink4a-ARF resulting in cellular proliferation [172]. Targeting the 
cyclin/CDK/RB pathway was investigated in a preclinical trial. PD-0332991 (PD), a CDK4/6 
inhibitor, was used in a genetically engineered, PDGF-B overexpressed, Ink4a-ARF and p53 
deficient brainstem glioma mouse model. PD induced cell cycle arrest both in vitro and in 
vivo. The survival of mice treated with PD alone or in combination with RT was significantly 
more than untreated or mice treated with only RT [172]. Inhibition WEE1 kinase, which is 
overexpressed in DIPG, was shown to increase the RT response in vitro and in vivo [73].
10.4. Immunotherapy
Interferon, IL-12 and anti-glioma monoclonal antibody have shown efficacy in mouse models 
of non-brainstem malignancies [173]. Recently, subcutaneous vaccinations with glioma-asso-
ciated antigen epitope peptides (EphA2, IL13-Rα2 and survivin) were investigated in children 
with DIPG. The vaccine was tolerated well and the results were encouraging for future trials 
[174]. IL13-Rα2 is of particular significance as it is highly and differentially expressed in DIPG 
[175, 176] compared to the normal brain tissue which makes it a suitable immunotherapy 
target.
10.5. Human neural and mesenchymal stem cells
Neural stem cells (NSC) have been utilized as the vehicle for therapeutic agents in gene ther-
apy for experimental malignant brain tumors [177, 178]. NSC have robust tumor tropism and 
this property can be used to deliver therapeutic agents to the inoperable DIPG tumors. NSC 
are difficult to harvest and use due to their inherent immunogenicity [179]. Mesenchymal 
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stem cells (MSC) have been found to be a suitable alternative as they have all the properties of 
NSC and are more practical to use [180]. In a rat model, brainstem glioma directed migratory 
capacities of NSC and MSC from different sources was found to be similar in vitro and in vivo. 
This study showed promise as 20–30% of stem cells migrated from the site of injection in the 
right forebrain to the brainstem glioma cells. In addition, the group treated with genetically 
engineered NSC encoding cytosine deaminase (CD) suicide gene and IFNβ proinflammatory 
cytokine and systemic 5-fluorouracil resulted in 59% reduction in the tumor size [181].
10.6. Delivery methods to overcome blood-brain barrier (BBB)
The vast majority of brain tumors are characterized by the loss of BBB integrity due to the 
disordered and highly permeable tumor neovasculature [182]. In DIPG, however, the BBB 
integrity is normal and the drug permeability is reduced as the tumor makes use of the exist-
ing brain vasculature [183]. Traditional cytotoxic drugs have shown good efficacy against 
DIPG cells in vitro but they likely fail to penetrate the BBB which may explain the contrasting 
results with clinical trials [28]. To overcome the disappointing results associated with sys-
temic therapy, methods utilizing localized and targeted drug delivery have been investigated.
10.6.1. Convection-enhanced delivery (CED)
CED is a relatively novel delivery modality which utilizes the properties of bulk flow to achieve 
homogeneously distributed infusions into the brain parenchyma [184]. It is a neurosurgical 
technique in which one to several catheters are stereotactically placed within or around the 
tumor mass and drug is delivered locally, bypassing the BBB and reducing systemic toxicity 
[185, 186]. The local concentrations achieved are significantly higher than the systemic admin-
istration and the drug distribution occurs along the patterns of the glioma cell invasion along 
the white matter tracts [187]. Many in vivo feasibility studies have confirmed that drugs can be 
safely delivered into the rodent brainstem [188]. CED of carmustine [74, 189], carboplatin [190, 
191], temozolomide [192], small-molecule kinase inhibitors [193], cisplatin [194] and gem-
citabine [190, 195] have been evaluated for safety and distribution parameters. Topotecan CED 
in two pediatric patients with DIPG showed initial reduction in tumor size [196]. MRI guided 
and robotically placed catheters were used for CED of carboplatin in DIPG patients. Three 
out of eight patients survived beyond 15 months and the procedure was tolerated well [197, 
198]. Administration of 124I-8H9, a radioactively labeled antibody and a chimeric toxin with 
B7-H3 specificity, is currently being explored in a phase I clinical trial for DIPG patients [199]. 
A patient with DIPG received CED infusion of the recombinant cytotoxin IL13-PE38QQR with 
GD-diethylenetriamine but the tumor progresses within a few weeks [200]. IL13-PE38QQR is 
a recombinant Pseudomonas aeruginosa toxin and some early phase clinical trials investigating 
its CED efficacy are being conducted or recently completed in patients with DIPG and HGG 
[185]. These studies have established the feasibility of CED. However, more data is required 
to prove safety and efficacy and CED models are undergoing rigorous investigations into the 
physical properties of the catheters and infusion rates [173]. CED targets the primary tumor 
only and not the metastatic sites. In DIPG, local and distant metastases in the brain or spine 
are seen in 13–17% patients. Therefore, in situations where disseminated disease is present, 
CED therapy alone, directed toward the primary tumor site, will be inadequate and should be 
complemented with therapies for the secondaries [28, 32].
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10.6.2. Nanoparticle delivery
Another alternative drug delivery technique involves encapsulation of cationic substances 
into capsules termed micro- and nanoparticles. This reduces their tissue affinity and increases 
the volume of distribution [28, 201].
10.6.3. Cell-mediated delivery
Bacterial cell-derived vehicles to transport chemotherapy agents across the BBB was uti-
lized with bi-specific antibodies recognizing cell wall and EGFR moieties [202]. Similar 
EGFR-targeted vehicles loaded with doxorubicin resulted in significant tumor regression in 
canine brain cancer models [203]. ECREST (A Study of Intravenous EEDVsMit in Children 
With Recurrent/Refractory Solid or CNS Tumors Expressing EGFR) is a phase I study using 
mitoxantrone loaded nanocells in EGFR positive relapsed/refractory solid and CNS tumors 
including DIPG [204].
10.6.4. BBB disruption techniques
BBB can be temporarily disrupted by ultrasound methods. This results in enhanced uptake of 
systemically delivered drugs [28].
11. Conclusion
DIPG remains the main cause of death in pediatric patients with brain tumors. Despite many 
clinical trials, minimal improvement has been achieved as compared with RT. Most of the 
clinical trials in the past did not have sound biological bases due to a lack of biopsy speci-
mens. In the last few years, international collaborative research has helped to identify new 
molecular aberrations in DIPG. These have provided insight into the pathogenesis of DIPG 
and may help in identifying new targeted therapies.
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